S&P Futures
3,441.25+18.50(+0.54%)Dow Futures
28,236.00+136.00(+0.48%)Nasdaq Futures
11,724.75+74.50(+0.64%)
Actinium Pharmaceuticals, Inc. (ATNM)
11.57 0.00 (0.00%)
After hours: 4:15PM EDT
Chart Events
Performance Outlook
| Previous Close | 11.98 |
| Open | 12.18 |
| Bid | 11.40 x 1100 |
| Ask | 11.57 x 4000 |
| Day's Range | 11.27 - 12.36 |
| 52 Week Range | 4.71 - 19.47 |
| Volume | 355,510 |
| Avg. Volume | 548,685 |
| Market Cap | 157.196M |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.06 |
| Earnings Date | Jun 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.33 |
- PR Newswire
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.
- Simply Wall St.
We Think Actinium Pharmaceuticals (NYSEMKT:ATNM) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.
